Accelerating Antibody Development with Automated Octet Assays
White Paper Mar 11, 2019
Drug development and production is challenging, however, high throughput characterization systems can greatly accelerate discovery programs.
Using a proprietary discovery and development platform technology, Avitide enables its partners to rapidly advance candidate molecules to the clinic and achieve faster and more predictable bioprocess development timelines.
Download this whitepaper to discover the key considerations for automated Octet assays.
Related White Papers
This document describes how Malvern Panalytical systems support system owners, meeting the requirements of the 21 CFR Part 11 regulations issued by the United States’ FDA.
READ MOREDownload this white paper to learn all about hybridoma-based antibody development, including their key benefits and misconceptions.
READ MOREDownload this white paper to understand how PerkinElmer’s Lead Discovery Premium can help deliver unified, interactive, responsive, data-agnostic access to all users.
READ MORELike what you just read? You can find similar content on the communities below.
Biopharma Cell Science DiagnosticsTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
